In last trading session, BridgeBio Pharma Inc (NASDAQ:BBIO) saw 1.47 million shares changing hands with its beta currently measuring 1.03. Company’s recent per share price level of $28.98 trading at $0.35 or 1.22% at ring of the bell on the day assigns it a market valuation of $5.35B. That closing price of BBIO’s stock is at a discount of -52.93% from its 52-week high price of $44.32 and is indicating a premium of 59.45% from its 52-week low price of $11.75. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.64 million shares which gives us an average trading volume of 1.86 million if we extend that period to 3-months.
BridgeBio Pharma Inc (NASDAQ:BBIO) trade information
Upright in the green during last session for gaining 1.22%, in the last five days BBIO remained trading in the green while hitting it’s week-highest on Thursday, 03/21/24 when the stock touched $28.98 price level, adding 3.66% to its value on the day. BridgeBio Pharma Inc’s shares saw a change of -28.21% in year-to-date performance and have moved 5.96% in past 5-day. BridgeBio Pharma Inc (NASDAQ:BBIO) showed a performance of -15.16% in past 30-days. Number of shares sold short was 13.64 million shares which calculate 8.54 days to cover the short interests.
BridgeBio Pharma Inc (BBIO) estimates and forecasts
Statistics highlight that BridgeBio Pharma Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 4.51% of value to its shares in past 6 months, showing an annual growth rate of 14.18% while that of industry is 21.20. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 1,399.80% from the last financial year’s standing.
5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $11.63 million for the same. And 7 analysts are in estimates of company making revenue of $3.6 million in the next quarter that will end on Jun 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -13.29% during past 5 years.
BBIO Dividends
BridgeBio Pharma Inc is more likely to be releasing its next quarterly report between May 02 and May 06 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
BridgeBio Pharma Inc (NASDAQ:BBIO)’s Major holders
Insiders are in possession of 5.37% of company’s total shares while institution are holding 91.93 percent of that, with stock having share float percentage of 97.15%. Investors also watch the number of corporate investors in a company very closely, which is 91.93% institutions for BridgeBio Pharma Inc that are currently holding shares of the company. Kohlberg Kravis Roberts & Co. L.P. is the top institutional holder at BBIO for having 31.06 million shares of worth $534.25 million. And as of Jun 29, 2023, it was holding 19.12% of the company’s outstanding shares.
The second largest institutional holder is Viking Global Investors, L.P., which was holding about 26.62 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 16.38% of outstanding shares, having a total worth of $457.88 million.
On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Aug 30, 2023, the former fund manager was holding 4.38 million shares of worth $130.98 million or 2.70% of the total outstanding shares. The later fund manager was in possession of 3.53 million shares on Jun 29, 2023, making its stake of worth around $60.69 million in the company or a holder of 2.17% of company’s stock.
